New ventures in the genotoxic and cytotoxic effects of macrocyclic lactones, Abamectin and Ivermectin

Cytogenetic and Genome Research

Volumn 128, Issue 1-3, 2010, Pages 37-45

  Molinari, G ^a   Soloneski, S ^a   Larramendy, Marcelo L ^a  

^a FACULTAD DE CIENCIAS NATURALES Y MUSEO   (Argentina)

Author keywords

Abamectin; Avermectins; Cytotoxicity; Genotoxicity; Ivermectin

Indexed keywords

4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID RECEPTOR; ABAMECTIN; ALBENDAZOLE; ANTIPARASITIC AGENT; CELL DNA; CHLORIDE CHANNEL; IVERMECTIN; LACTONE DERIVATIVE; PESTICIDE;

AMES TEST; ANTHELMINTIC ACTIVITY; ANTIBIOTIC BIOSYNTHESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BIOASSAY; CARCINOMA; CELL CYCLE PROGRESSION; CHROMOSOME ABERRATION; CYTOTOXICITY; DNA STRAND BREAKAGE; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; EHRLICH ASCITES TUMOR; GENE MUTATION; GENOTOXICITY; HUMAN; LYMPHATIC FILARIASIS; LYSOSOME MEMBRANE; MEMBRANE STABILIZATION; MITOSIS INHIBITION; NEUROMUSCULAR SYNAPSE; NEUROTRANSMISSION; NONHUMAN; ONCHOCERCIASIS; PRIORITY JOURNAL; REVIEW; SISTER CHROMATID EXCHANGE; STREPTOMYCES;

ANIMALS; ANTHELMINTICS; CELL LINE; DNA DAMAGE; HUMANS; IVERMECTIN; PESTICIDES;

BACTERIA (MICROORGANISMS); MAMMALIA; STREPTOMYCES AVERMITILIS;

EID: 77953289630     PISSN: 14248581     EISSN: None     Source Type: Journal    
DOI: 10.1159/000293923     Document Type: Review

References (69)

1. Agarwal AK: Avermectin, in Wexler P (ed): Encyclopedia of Toxicology, pp 89-90 (Academic Press, San Diego 1998).
2. Aleksić N, Barjaktarović N: Investigation on sister chromatid exchange (SCE) by Ivermectin. Genetika 25: 219-225 (1993).
3. Aleksić N, Milutinović M, Bakrać T: Investigation of the genotoxic effects of Ivermectin on human lymphocytes. Acta Vet Brno 46: 51-55 (1996).
4. Blazak WF, Mitchell AD, Skinner WA: An assessment of the mutagenic potential of Abamectin (mk 0936) utilizing the in vivo mouse bone marrow cytogenetics assay. Study Number TT 83-900-906 Unpublished report prepared by SRI International, Menlo Park, CA, USA. Submitted to WHO by MSDRL, Three Bridges, NJ, USA. (1983).
5. Bonatti S, Bolognesi C, Degan P, Abbondandolo A: Genotoxic effects of the carbamate insecticide methomyl. I. In vitro studies with pure compound and the technical formulation "Lannate 25". Environ Mol Mutagen 23: 306-311 (1994). (Pubitemid 24227889)
6. Boxall A, Long C: Veterinary medicines and the environment. Environ Toxicol Chem 24: 759-760 (2005).
7. Burg RW, Miller BM, Baker EE, Birnbaum J, Currie SA, et al: Avermectins, new family of potent anthelmintic agents: producing organism and fermentation. Antimicrob Agents Chemother 15: 361-367 (1979).
8. Burg RW, Stapley EO: Isolation and characterization of the producing organism, in Campbell WC (ed): Ivermectin and Abamectin, pp 24-32 (Springer, New York 1989).
9. Campbell WC, Benz GW: Ivermectin: a review of efficacy and safety. J Vet Pharmacol Ther 7: 1-16 (1984).
10. Campbell WC, Fisher MH, Stapley EO, Albers-Schönberg G, Jacob TA: Ivermectin: a potent new antiparasitic agent. Science 221: 823-828 (1983).
11. Carbonell E, Valbuena A, Xamena N, Creus A, Marcos R: Temporary variations in chromosomal aberrations in a group of agricultural workers exposed to pesticides. Mutat Res 344: 127-134 (1995).
12. Chabala JC, Mrozik H, Tolman RL, Eskola P, Lusi A, et al: Ivermectin, a new broad-spectrum antiparasitic agent. J Med Chem 23: 1134-1136 (1980).
13. Chauhan LK, Kumar M, Paul BN, Goel SK, Gupta SK: Cytogenetic effects of commercial formulations of deltamethrin and/or isoproturon on human peripheral lymphocytes and mouse bone marrow cells. Environ Mol Mutagen 48: 636-648 (2007).
14. Das PP, Shaik AP, Jamil K: Genotoxicity induced by pesticide mixtures: in-vitro studies on human peripheral blood lymphocytes. Toxicol Ind Health 23: 449-458 (2007).
15. Drinyaev VA, Mosin VA, Kruglyak EB, Novik TS, Sterlina TS, et al: Antitumor effect of avermectins. Eur J Pharmacol 501: 19-23 (2004).
16. Egerton JR, Ostlind DA, Blair LS, Eary CH, Suhayda D, et al: Avermectins, new family of potent anthelmintic agents: efficacy of the B1a component. Antimicrob Agents Chemother 15: 372-378 (1979).
17. EPA: A Common Mechanism of Action: The Organophosphate Pesticides. Report to the Science Advisory Panel 13 February 1998. (1998).
18. EPA: Guidance for Identifying Pesticide Chemicals and other Substances that have a Common Mechanism of Toxicity, pp 1-14 (Office of Pesticide Programs, Office of Prevention Pesticides and Toxic Substances, Washington DC 1999).
19. EPA: A Common Mechanism of Toxicity Determination for N-Methyl Carbamate Pesticides. Memorandum July 10 2001. (2001).
20. EPA: The Grouping of a Series of Triazine Pesticides based on a Common Mechanism of Toxicity, (Office of Pesticide Programs Health Effects Division, Washington, DC 2002).
21. Fisher MH, Mrozik H: Chemistry, in Campbell WC (ed): Ivermectin and Abamectin, pp 1-23 (Springer-Verlag, New York 1989).
22. Georgieva V, Vachkova R, Tzoneva M, Kappas A: Genotoxic activity of benomyl in different test systems. Environ Mol Mutagen 16: 32-36 (1990).
23. Gordon LR, Bradley MO, Cook MM, Berglund RM, Prato M: Microbial mutagen test on abamectin (MK 0936) with and without rat liver enzyme activation. Study No. TT 82-8013. Unpublished report prepared by Merck Sharp Dohme Research Laboratories, West Point, Pennsylvania, USA. Submitted to WHO by MSDRL, Three Bridges, NJ, USA. (1982a).
24. Gordon LR, Bradley MO, Patterson S: V-79 mammalian cell mutagenesis assay with abamectin (MK 0936). Study No. TT 82-8506, 82-8510, 82-8512, 82-8519. Unpublished report prepared by Merck Sharp & Dohme Research Laboratories, West Point, Pennsylvania, USA. Submitted to WHO by MSDRL, Three Bridges, NJ, USA. (1982b).
25. Gordon LR, Bradley MO, Patterson SK, Taylor VE, Dysart GR: In vivo alkaline elution/rat hepatocyte assay with abamectin (MK 0936). Study No. TT 82-8302. Unpublished report prepared by Merck Sharp & Dohme Research Laboratories, West Point, Pennsylvania, USA. Submitted to WHO by MSDRL, Three Bridges, NJ, USA. (1982c).
26. Gordon LR, Bradley MO, Patterson SK, Taylor VE, Dysart GR: In vitro alkaline elution/rat hepatocyte assay with abamectin (MK 0936). Study No. TT 82-8520, 82-8523, 82-8525, 82-8526. Unpublished report prepared by Merck Sharp & Dohme Research Laboratories, West Point, Pennsylvania, USA. Submitted to WHO by MSDRL, Three Bridges, NJ, USA. (1982d).
27. Gordon LR, Galloway S, Patterson SK, Armstrong M, Bean CL, Deasy D: Abamectin (MK 0936) assay for chromosomal aberrations in vitro, in Chinese hamster ovary cells Study No. TT 85-8631, 85-8632, 85-8635. Unpublished report prepared by Merck Sharp & Dohme Research Laboratories, West Point, Pennsylvania, USA. Submitted to WHO by MSDRL, Three Bridges, NJ, USA. (1985a).
28. Gordon LR, Sina J, Patterson S, Berglind R, Prato M, Quillin F: Microbial mutagenesis assays with abamectin (avermectin B1; MK 0936). Study No. TT 85-8005 and 85-805. Unpublished reports prepared by Merck Sharp & Dohme Research Laboratories, West Point, Pennsylvania, USA. Submitted to WHO by MSDRL, Three Bridges, NJ, USA. (1985b).
29. Gordon LR, Sina JF, Wright SP, Prato M, Quillin F: Microbial mutagenesis assays of the Delta-8,9-isomer and polar degradates of abamectin (Avermectin B1; MK 0936). Study Nos. TT 87-8046, 87-8047, 87-8058. Unpublished reports prepared by Merck Sharp & Dohme Research Laboratories, West Point, Pennsylvania, USA.Submitted to WHO by MSDRL, Three Bridges, NJ, USA. (1987).
30. Ikeda H, Ǒmura S: Control of avermectin biosynthesis in Streptomyces avermitilis for the selective production of a useful component. J Antibiot 48: 549-562 (1995).
31. Ikeda H, Ǒmura S: Avermectin biosynthesis. Chem Rev 97: 2591-2610 (1997).
32. Ikeda H, Ishikawa J, Hanamoto A, Shinose M, Kikuchi H, et al: Complete genome sequence and comparative analysis of the industrial microorganism Streptomyces avermitilis . Nat Biotechnol 21: 526-531 (2003).
33. ILSI: A Framework for Cumulative Risk Assessment, pp 1-62 (International Life Science Institute, Washington, DC 1999).
34. Jablonická A, Poláková H, Karelová J, Vargová M: Analysis of chromosome aberrations and sister-chromatid exchanges in peripheral blood lymphocytes of workers with occupational exposure to the mancozeb-containing fungicide Novozir Mn80. Mutat Res 224: 143-146 (1989).
35. Jensen J, Diao X, Scott-Fordsmand JJ: Sub-lethal toxicity of the antiparasitic abamectin on earthworms and the application of neutral red retention time as a biomarker. Chemosphere 68: 744-750 (2007).
36. Kaplan RM, Courtney CH, Kunkle WE, Zeng QY, Jernigan AD, Eagleson JS: Efficacy of injectable abamectin against gastrointestinal tract nematodes and lungworms of cattle. Am J Vet Res 55: 353-357 (1994).
37. Kita K, Shiomi K, Omura S: Advances in drug discovery and biochemical studies. Trends Parasitol 23: 223-229 (2007).
38. Kocaman AY, Topaktaş M: The in vitro genotoxic effects of a commercial formulation of alpha-cypermethrin in human peripheral blood lymphocytes. Environ Mol Mutagen 50: 27-36 (2009).
39. Korystov YN, Mosin VA, Shaposhnikova VV, Levitman MK, Kudryavtsev AA, et al: A comparative study of effects of Aversectin C, Abamectin and Ivermectin on apoptosis of rat thymocytes induced by radiation and dexamethasone. Acta Vet Brno 68: 23-29 (1999).
40. Korystov YN, Ermakova NV, Kublik LN, Levitman MK, Shaposhnikova VV, et al: Avermectins inhibit multidrug resistance of tumor cells. Eur J Pharmacol 493: 57-64 (2004).
41. Lankas GR, Gordon LR: Toxicology, in Campbell WC (ed): Ivermectin and Abamectin, pp 89-112 (Springer-Verlag, New York 1989).
42. McCavera S, Walsh TK, Wolstenholme AJ: Nematode ligand-gated chloride channels: an appraisal of their involvement in macrocyclic lactone resistance and prospects for developing molecular markers. Parasitology 134: 1111-1121 (2007).
43. Merck and Co. I: MK-0933: microbial mutagen test with and without rat liver enzyme activation. TT #77-8068. Unpublished study; submitted to WHO by Merck & Co., Inc. (1978).
44. Merck and Co. I: MK-0933: Mouse lymphoma cytotoxicity study. TT #79-8034. Unpublished study; submitted to WHO by Merck & Co., Inc. (1980a).
45. Merck and Co. I: MK 933: Unscheduled DNA synthesis in human IMR90-fibroblasts. TT #80-8205. Unpublished study; submitted to WHO by Merck & Co., Inc. (1980b).
46. Merck and Co. I: Ninety-four week dietary carcinogenicity and toxicity study in mice. TT #83-002,-0, -1, -2, -3. Unpublished study; submitted to WHO by Merck & Co., Inc. (1983).
47. Miller TW, Chaiet L, Cole DJ, Cole LJ, Flor JE, et al: Avermectins, new family of potent anthelmintic agents: isolation and chromatographic properties. Antimicrob Agents Chemother 15: 368-371 (1979).
48. Molinari G, Soloneski S, Reigosa MA, Larramendy ML: In vitro genotoxic and cytotoxic effects of ivermectin and its formulation ivomec on Chinese hamster ovary (CHOK1) cells. J Hazard Mater 165: 1074-1082 (2009).
49. Molyneux DH, Zagaria N: Lymphatic filariasis elimination: progress in global programme development. Ann Trop Med Parasitol 96:S15-S40 (2002).
50. Molyneux DH, Hopkins DR, Zagaria N: Disease eradication, elimination and control: the need for accurate and consistent usage. Trends Parasitol 20: 347-351 (2004).
51. Mosin VA, Krugliak EB, Sterlina TS, Korystov IN, Shaposhnikova VV, et al: Cytotoxic and cytostatic effect of avermectines on tumor cells in vitro. Antibiot Khimioter 45: 10-14 (2000).
52. Olsen A: Efficacy and safety of drug combinations in the treatment of schistosomiasis, soil-transmitted helminthiasis, lymphatic filariasis and onchocerciasis. Trans R Soc Trop Med Hyg 101: 747-758 (2007).
53. Ǒmura S: Mode of action of avermectin, in Omura S (ed): Macrolide Antibiotics: Chemistry, Biology and Practice, pp 571-776 (Academic Press, New York 2002).
54. Ǒmura S: Ivermectin: 25 years and still going strong. Int J Antimicrob Agents 31: 91-98 (2008).
55. Ǒmura S, Crump A: The life and times of ivermectin - a success story. Nat Rev Microbiol 2: 984-989 (2004).
56. Ǒmura S, Ikeda H, Ishikawa J, Hanamoto A, Takahashi C, et al: Genome sequence of an industrial microorganism Streptomyces avermitilis : deducing the ability of producing secondary metabolites. Proc Natl Acad Sci USA 98: 12215-12220 (2001).
57. Pitterna T, Cassayre J, Hüter OF, Jung PM, Maienfisch P, et al: New ventures in the chemistry of avermectins. Bioorg Med Chem 17: 4085-4095 (2009).
58. Ribas G, Surrallés J, Carbonell E, Xamena N, Creus A, Marcos R: Genotoxic evaluation of the herbicide paraquat in cultured human lymphocytes. Teratog Carcinog Mutagen 17: 339-347 (1997).
59. Skeggs H: Microbial mutagenesis assay with avermectin B1a (C-076(B1a)). Study No. TT 76-8052. Unpublished report prepared by Merck Sharp & Dohme Research Laboratories, West Point, Pennsylvania, USA. Submitted to WHO by MSDRL, Three Bridges, NJ, USA. (1976).
60. Soloneski S, González M, Piaggio E, Apezteguía M, Reigosa MA, Larramendy ML: Effect of the dithiocarbamate pesticide zineb and its commercial formulation azzurro. I. Genotoxic evaluation on cultured human lymphocytes exposed in vitro. Mutagenesis 16: 487-493 (2001).
61. Stapley EO, Woodruff HB: Avermectins, antiparasitic lactones produced by Streptomyces avermitilis isolated from a soil in Japan: Proceedings of an International Conference on Trends in Antibiotic Research: Genetics, Biosyntheses, Actions and New substances, pp 154-170 (Japan Antibiotic Research Association, Tokyo 1982).
62. Sunazuka T, Omura S, Iwasaki S, Ǒmura S: Chemical modifications of macrolides, in Ǒmura S (ed): Macrolide Antibiotics Chemistry, Biology, and Practice, pp 99-180 (Elsevier Inc, New York 2003).
63. Takahashi Y, Matsumoto A, Seino A, Ueno J, Iwai Y, Omura S: Streptomyces avermectinius sp. nov., an avermectin-producing strain. Int J Antimicrob Agents 52: 2163-2168 (2002).
64. Wei L, Wei G, Zhang H, Wang PG, Du Y: Synthesis of new, potent avermectin-like insecticidal agents. Carbohydr Res 340: 1583-1590 (2005).
65. Winnen M, Plaisier AP, Alley ES, Nagelkerke NJ, van Oortmarssen G, et al: Can ivermectin mass treatments eliminate onchocerciasis in Africa? Bull World Health Organ 80: 384-391 (2002).
66. Woods DJ, Williams TM: The challenges of developing novel antiparasitic drugs. Invert Neurosci 7: 245-250 (2007).
67. Xu Y, Guo H, Xiao Q, Su F, Yin L: In vitro acute cytotoxicity of abamectin to the Gill Cell Line of Flounder Paralichthy olivaceus . J Ocean Univ China 6: 369-372 (2007).
68. Yoon YJ, Kim ES, Hwang YS, Choi CY: Avermectin: biochemical and molecular basis of its biosynthesis and regulation. Appl Microbiol Biotechnol 63: 626-634 (2004).
69. Zhang X, Chen Z, Li M, Wen Y, Song Y, Li J: Construction of ivermectin producer by domain swaps of avermectin polyketide synthase in Streptomyces avermitilis . Appl Microbiol Biotechnol 72: 986-994 (2006).